Primary tabs

Other Access

The information on this page (the dataset metadata) is also available in these formats.

JSON RDF

via the DKAN API

Belgian Hepatitis C Registry

The reimbursement conditions for 6 specific types of antiviral hepatitis C medication for the treatment of chronic hepatitis C patients will be extended and 2 new ones will be added[1]. This extended reimbursement will be active starting from 1.1.2017 and is agreed upon for a period of 2 years between RIZIV-INAMI and the 5 involved pharmaceutical companies via a contract of type Art.81 signed with the RIZIV-INAMI..

The hepatitis C antiviral medication is on the list of Chapter 4 medication, which requires the treating physician to fill out a dedicated form to apply for reimbursement. Apart from this information, the treating physician is also obliged to participate in the registration of follow-up data of his/her patients using this antiviral hepatitis C medication.

[1] The 8 pharmaceuticals involved are HARVONI, EXVIERA, VIEKIRAX, DAKLINZA, OLYSIO, SOVALDI, EPCLUSA (new) and ZEPATIER (new).

FieldValue
Modified
2020-07-20
Release Date
2018-03-27
Identifier
e7b305c8-433b-43b8-8952-82f162dffdba
License
Public Access Level
Public